Intellia Therapeutics, Inc. announces appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Published on 10/13/2026 at 10:21 am EDT S&P Capital IQ Intellia Therapeutics, Inc. announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company?s translational, development, regulatory and medical affairs functions. Dr. Marantz?s leadership experience spans research and development, medical affairs, business development and portfolio strategy across multiple specialties and rare diseases. Most recently, she served as Chief Medical Officer for Scholar Rock, where she led the development organization in advancing multiple clinical programs across neuromuscular, oncology and obesity, culminating in the U.S. approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. During her tenure at Scholar Rock, Dr. Marantz led simultaneous regulatory submissions to the U.S. Food and Drug Administration and European Medicines Agency followed by successful engagement with Japan?s Pharmaceuticals and Medical Devices Agency, achieving alignment for a Japanese New Drug Application submission without clinical trial data in Japanese patients. Prior to her role at Scholar Rock, Dr. Marantz held senior leadership positions at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD and Millennium Pharmaceuticals, playing key roles in the development and commercialization of over a dozen products across hematology/oncology, neurology and rare diseases. She is a member of the Board of Directors for Arcturus Therapeutics, Inc. Dr. Marantz received her medical training from Tongji Medical College, a Ph.D. in Biochemistry and Molecular Biology from the Medical University of South Carolina, and an MBA from the University of California at Berkeley. (C) S&P Capital IQ - 2026

Intellia Therapeutics has appointed Jing L. Marantz as executive vice president and chief medical officer, effective October 26, 2026. She will lead the company's translational, development, regulatory, and medical affairs functions. Marantz has more than 25 years of experience in biopharmaceuticals. She was most recently chief medical officer at Scholar Rock, where she oversaw the US approval of ISEMBYLD, the first muscle-targeted therapy for Spinal Muscular Atrophy. She also held senior roles at Krystal Biotech, Acceleron, Alnylam, Alexion, Biogen, ARIAD, and Millennium Pharmaceuticals. Chief executive officer John Leonard said her experience will be critical as Intellia seeks to commercialise its first potential in vivo gene editing product and advances Phase 3 trials in transthyretin amyloidosis.

CRISPR Therapeutics outlook: scaling gene editing by 2036. Key takeaways. * CRISPR Therapeutics currently reports $10.2 million in quarterly revenue against a $91.2 million net loss, highlighting the heavy R&D burden of its current pipeline. * The company is pivoting from ex-vivo therapies like Casgevy toward in-vivo editing, which could expand its addressable patient population from 150,000 to 400,000. * By 2036, the success of SyNTase editing and in-vivo delivery methods will determine if the firm transitions from a niche biotech to a diversified genomic medicine powerhouse. TrendPulse analysis. Industry context. The gene-editing landscape is moving beyond the "proof of concept" phase into a period of rigorous commercial validation. Historically, the sector has been defined by high-cost, one-time curative treatments. However, the industry is now facing a "delivery bottleneck." Competitors like **Intellia Therapeutics** and **Beam Therapeutics** are also racing to solve the in-vivo delivery challenge, as the market increasingly favors standardized, off-the-shelf products over the bespoke, patient-specific manufacturing processes that currently dominate the space. Furthermore, the regulatory environment is becoming more sophisticated. As seen with recent setbacks at major pharmaceutical firms like **Novartis**, regulators are no longer satisfied with biomarker improvements alone. They now demand clear, long-term clinical outcomes that translate into tangible patient health benefits. This shift forces companies like CRISPR Therapeutics to prove not just that they can edit a gene, but that the edit reliably prevents disease progression in real-world settings. The industry is effectively moving from a "technology-first" mindset to a "clinical-outcome-first" mandate. Why this matters. For investors and industry stakeholders, the next decade represents a transition from speculative growth to operational maturity. The primary risk is no longer just scientific failure, but commercial viability. If CRISPR Therapeutics successfully transitions to in-vivo delivery, it will fundamentally change the economics of the business, moving from a high-cost service model to a scalable product model. This would likely trigger a wave of M&A activity, as large-cap pharmaceutical companies look to acquire proven, scalable genomic platforms to replenish their aging pipelines. However, the path to 2036 is fraught with "clinical disconnect" risks - where the editing works, but the patient outcome does not improve as expected. Decision-makers should monitor the company's ability to manage its cash burn while navigating these long-term trials. The winners in this space will be those who can balance the high costs of R&D with a clear, cost-effective path to commercialization. Investors should look for evidence of manufacturing efficiency and partnerships that can handle the global distribution of these complex therapies once they reach the market. The bottom line. CRISPR Therapeutics' long-term value hinges on its ability to transition from complex, ex-vivo procedures to scalable in-vivo therapies that deliver measurable, long-term clinical outcomes. Read the full article. This analysis is based on reporting from nasdaq Finance AI-powered news analysis · September 18, 2026 Editorially Reviewed